In BC, FBXO22 determines the sensitivity of endocrine treatment by making KDM4B ubiquitination complexed with unliganded or selective estrogen receptor modulators (SERMs)‐bound estrogen receptor (ER) [18]. Here, FBXO22 is linked to breast cancer.